Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GBS Inc. (GBS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5074-0.0127 (-2.44%)
At close: 04:00PM EDT
Advertisement

GBS Inc.

142 West 57th Street
11th Floor
New York, NY 10019
United States
646 828 8258
https://gbs.inc

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D.Interim CEO & Chairman85.64kN/A1958
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip LawChief Financial Officer292.45kN/A1962
Mr. Harry SimeonidisPres of Asia Pacific354.71kN/A1969
Ms. Victoria GavrilenkoOperations Mang.N/AN/A1983
Mr. Alex ArzenoVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Corporate Governance

GBS Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement